
Asia Pacific Hepatitis B Infection Market
Description
Asia Pacific Hepatitis B Infection Market
The Asia-Pacific hepatitis B infection market is expected to reach USD 6.52 billion by 2031 from USD 4.03 billion in 2023, growing at a CAGR of 6.2% in the forecast period of 2024 to 2031.
Asia-Pacific Hepatitis B Infection Market Segmentation, By Type (Chronic and Acute), By treatment (Vaccine, Antiviral Drugs, Immune Modulator Drugs, and Surgery, By Countries (China, India, Japan, South Korea, Singapore, Thailand, Malaysia, Indonesia, Australia, Vietnam, New Zealand, Taiwan, Philippines, and rest of Asia-Pacific)- Industry Trends and Forecast to 2031
Overview of Asia-Pacific Hepatitis B infection Market Dynamics:
Driver
• Increasing prevalence of hepatitis B infections
Restraint
• Side effects and drug resistance
Opportunity
• Advanced research and development for clinical trials
Market Players:
The key market players operating in the Asia-Pacific hepatitis B infection market are listed below:
• Gilead Sciences, Inc.
• GSK plc
• F. Hoffmann-La Roche Ltd
• Bristol-Myers Squibb
Table of Contents
180 Pages
- 1 Introduction
- 1.1 Objectives Of The Study
- 1.2 Market Definition
- 1.3 Overview Of Asia-pacific Hepatitis B Infection Market
- 1.4 Markets Covered
- 2 Market Segmentation
- 2.1 Markets Covered
- 2.2 Geographical Scope
- 2.3 Years Considered For The Study
- 2.4 Currency And Pricing
- 2.5 Dbmr Tripod Data Validation Model
- 2.6 Multivariate Modelling
- 2.7 Therapeutics Lifeline Curve
- 2.8 Primary Interviews With Key Opinion Leaders
- 2.9 Dbmr Market Position Grid
- 2.10 Vendor Share Analysis
- 2.11 Secondary Sources
- 2.12 Assumptions
- 3 Executive Summary
- 4 Premium Insight
- 4.1 Pestal Analysis
- 4.2 Porter Five Forces
- 5 Asia-pacific Hepatitis B Infection Market: Regulations
- 5.1 Regulatory Authorities In The Asia-pacific Region
- 5.2 North America Regulatory Scenario
- 5.3 Europe Regulatory Scenario
- 5.4 Middle East And Africa Regulatory Scenario
- 5.5 South America Regulatory Scenario
- 6 Pipeline Analysis
- 7 Epidemiliogy
- 8 Market Overview
- 8.1 Drivers
- 8.1.1 Increasing Prevalence Of Hepatitis B Infections
- 8.1.2 Technological Advancements In Diagnostics
- 8.1.3 Development Of Combination Therapies For Hepatitis B
- 8.1.4 Strategic Initiatives By Companies For Hepatitis B Infection
- 8.2 Restraints
- 8.2.1 Side Effects And Drug Resistance
- 8.2.2 Insufficient Vaccine Coverage For Hepatitis B Infection
- 8.3 Opportunity
- 8.3.1 Rising New Drug Releases And Increasing New Drug Permits For Hepatitis B
- 8.3.2 Government Programs To Raise Awareness Of Hepatitis B Infection
- 8.3.3 Advanced Research And Development For Clinical Trials
- 8.4 Challenges
- 8.4.1 The Cost Of Hepatitis B Treatments Is High
- 8.4.2 Stringent Regulatory Policies And Regional Disparities In Treatment Access
- 9 Asia-pacific Hepatitis B Infection Market, By Type
- 9.1 Overview
- 9.2 Chronic
- 9.3 Acute
- 10 Asia-pacific Hepatitis B Infection Market, By Treatment
- 10.1 Overview
- 10.2 Vaccine
- 10.2.1 Hospital Pharmacies
- 10.2.2 Drugs Stores And Retail Pharmacies
- 10.2.3 Online Pharmacies
- 10.3 Antiviral Drugs
- 10.3.1 Tenofovir Alafenamide Fumarate (Taf)
- 10.3.2 Tenofovir Disoproxil Fumarate (Tdf)
- 10.3.3 Entecavir
- 10.3.4 Others
- 10.4 Immune Modulator Drugs
- 10.4.1 Pegylated Interferon
- 10.4.2 Interferon Alpha
- 10.5 Surgery
- 11 Asia-pacific Hepatitis B Infection Market, By Region
- 11.1 Asia-pacific
- 11.1.1 China
- 11.1.2 India
- 11.1.3 Indonesia
- 11.1.4 Japan
- 11.1.5 Vietnam
- 11.1.6 Philippines
- 11.1.7 Thailand
- 11.1.8 South Korea
- 11.1.9 Australia
- 11.1.10 Singapore
- 11.1.11 Malaysia
- 11.1.12 New Zealand
- 11.1.13 Taiwan
- 11.1.14 Rest Of Asia-pacific
- 12 Asia-pacific Hepatitis B Treatment Market: Company Landscape
- 12.1 Company Share Analysis: Asia-pacific
- 13 Swot Analysis
- 14 Company Profile
- 14.1 Gilead Sciences, Inc.
- 14.1.1 Company Snapshot
- 14.1.2 Revenue Analysis
- 14.1.3 Company Share Analysis
- 14.1.4 Product Portfolio
- 14.1.5 Recent Development
- 14.2 Glaxosmithkline Plc
- 14.2.1 Company Snapshot
- 14.2.2 Revenue Analysis
- 14.2.3 Company Share Analysis
- 14.2.4 Product Portfolio
- 14.2.5 Recent Development
- 14.3 Dynavax Technologies Corporation
- 14.3.1 Company Snapshot
- 14.3.2 Revenue Analysis
- 14.3.3 Company Share Analysis
- 14.3.4 Product Portfolio
- 14.3.5 Recent Developments
- 14.4 F. Hoffman-la Roche Ltd.
- 14.4.1 Company Snapshot
- 14.4.2 Revenue Analysis
- 14.4.3 Company Share Analysis
- 14.4.4 Product Portfolio
- 14.4.5 Recent Developments
- 14.5 Bristol-myers Squibb Company
- 14.5.1 Company Snapshot
- 14.5.2 Revenue Analysis
- 14.5.3 Company Share Analysis
- 14.5.4 Product Portfolio
- 14.5.5 Recent Developments
- 14.6 Arrowhead Pharmaceuticals, Inc.
- 14.6.1 Company Snapshot
- 14.6.2 Revenue Analysis
- 14.6.3 Product Portfolio
- 14.6.4 Recent Developments
- 14.7 Arbutus Biopharma
- 14.7.1 Company Snapshot
- 14.7.2 Revenue Analysis
- 14.7.3 Product Portfolio
- 14.7.4 Recent Updates
- 14.8 Aurobindo Pharma
- 14.8.1 Company Snapshot
- 14.8.2 Revenue Analysis
- 14.8.3 Product Portfolio
- 14.8.4 Recent Updates
- 14.9 Lupin Pharmaceuticals, Inc.
- 14.9.1 Company Snapshot
- 14.9.2 Product Portfolio
- 14.9.3 Recent Updates
- 14.10 Merck & Co., Inc.,
- 14.10.1 Company Snapshot
- 14.10.2 Revenue Analysis
- 14.10.3 Product Portfolio
- 14.10.4 Recent Developments
- 14.11 Novartis Ag
- 14.11.1 Company Snapshot
- 14.11.2 Revenue
- 14.11.3 Product Portfolio
- 14.11.4 Recent Development
- 14.12 Teva Pharmaceutical Industries
- 14.12.1 Company Snapshot
- 14.12.2 Product Portfolio
- 14.12.3 Recent Developments
- 14.13 Zydus Pharmaceuticals, Inc.
- 14.13.1 Company Snapshot
- 14.13.2 Product Portfolio
- 14.13.3 Revenue
- 14.13.4 Recent Development
- 15 Questionnaire
- 16 Related Reports
- Table 1 Asia-pacific Clinical Trial And Pipeline A-lysis As Per The Company
- Table 2 Distribution Of Products Or Projects By Phase
- Table 3 Country Wise Epidemiology For Hepatitis B
- Table 4 Cost Of Hepatitis B Medications: Brand Vs. Generic Prices
- Table 5 Asia-pacific Hepatitis B Infection Market, By Type, 2022-2031 (Usd Million)
- Table 6 Asia-pacific Chronic In Hepatitis B Infection Market, By Region, 2022-2031 (Usd Million)
- Table 7 Asia-pacific Acute In Hepatitis B Infection Market, By Region, 2022-2031 (Usd Million)
- Table 8 Asia-pacific Hepatitis B Infection Market, By Treatment, 2022-2031 (Usd Million)
- Table 9 Asia-pacific Vaccine In Hepatitis B Infection Market, By Region, 2022-2031 (Usd Million)
- Table 10 Asia-pacific Vaccine, Antiviral Drugs, Immune Modulator Drugs In Hepatitis B Infection Market, By Distribution Channel, 2022-2031 (Usd Million)
- Table 11 Asia-pacific Antiviral Drugs In Hepatitis B Infection Market, By Region, 2022-2031 (Usd Million)
- Table 12 Asia-pacific Antiviral Drugs In Hepatitis B Infection Market, By Treatment, 2022-2031 (Usd Million)
- Table 13 Asia-pacific Immune Modulator Drugs In Hepatitis B Infection Market, By Region, 2022-2031 (Usd Million)
- Table 14 Asia-pacific Immune Modulator Drugs In Hepatitis B Infection Market, By Treatment, 2022-2031 (Usd Million)
- Table 15 Asia-pacific Surgery In Hepatitis B Infection Market, By Region, 2022-2031 (Usd Million)
- Table 16 Asia-pacific Hepatitis B Infection Market, By Country, 2022-2031 (Usd Million)
- Table 17 Asia-pacific Hepatitis B Infection Market, By Type, 2022-2031 (Usd Million)
- Table 18 Asia-pacific Hepatitis B Infection Market, By Treatment, 2022-2031 (Usd Million)
- Table 19 Asia-pacific Antiviral Drugs In Hepatitis B Infection Market, By Treatment, 2022-2031 (Usd Million)
- Table 20 Asia-pacific Immune Modulator Drugs In Hepatitis B Infection Market, By Treatment, 2022-2031 (Usd Million)
- Table 21 China Vaccine, Antiviral Drugs, Immune Modulator Drugs In Hepatitis B Infection Market, By Distribution Channel, 2022-2031 (Usd Million)
- Table 22 China Hepatitis B Infection Market, By Treatment, 2022-2031 (Usd Million)
- Table 23 China Hepatitis B Infection Market, By Treatment, 2022-2031 (Usd Million)
- Table 24 China Antiviral Drugs In Hepatitis B Infection Market, By Treatment, 2022-2031 (Usd Million)
- Table 25 China Immune Modulator Drugs In Hepatitis B Infection Market, By Treatment, 2022-2031 (Usd Million)
- Table 26 China Vaccine, Antiviral Drugs, Immune Modulator Drugs In Hepatitis B Infection Market, By Distribution Channel, 2022-2031 (Usd Million)
- Table 27 India Hepatitis B Infection Market, By Type, 2022-2031 (Usd Million)
- Table 28 India Hepatitis B Infection Market, By Treatment, 2022-2031 (Usd Million)
- Table 29 India Antiviral Drugs In Hepatitis B Infection Market, By Treatment, 2022-2031 (Usd Million)
- Table 30 India Immune Modulator Drugs In Hepatitis B Infection Market, By Treatment, 2022-2031 (Usd Million)
- Table 31 India Vaccine, Antiviral Drugs, Immune Modulator Drugs In Hepatitis B Infection Market, By Distribution Channel, 2022-2031 (Usd Million)
- Table 32 Indonesia Hepatitis B Infection Market, By Type, 2022-2031 (Usd Million)
- Table 33 Indonesia Hepatitis B Infection Market, By Treatment, 2022-2031 (Usd Million)
- Table 34 Indonesia Antiviral Drugs In Hepatitis B Infection Market, By Treatment, 2022-2031 (Usd Million)
- Table 35 Indonesia Immune Modulator Drugs In Hepatitis B Infection Market, By Treatment, 2022-2031 (Usd Million)
- Table 36 Indonesia Vaccine, Antiviral Drugs, Immune Modulator Drugs In Hepatitis B Infection Market, By Distribution Channel, 2022-2031 (Usd Million)
- Table 37 Japan Hepatitis B Infection Market, By Type, 2022-2031 (Usd Million)
- Table 38 Japan Hepatitis B Infection Market, By Treatment, 2022-2031 (Usd Million)
- Table 39 Japan Antiviral Drugs In Hepatitis B Infection Market, By Treatment, 2022-2031 (Usd Million)
- Table 40 Japan Immune Modulator Drugs In Hepatitis B Infection Market, By Treatment, 2022-2031 (Usd Million)
- Table 41 Japan Vaccine, Antiviral Drugs, Immune Modulator Drugs In Hepatitis B Infection Market, By Distribution Channel, 2022-2031 (Usd Million)
- Table 42 Vietnam Hepatitis B Infection Market, By Type, 2022-2031 (Usd Million)
- Table 43 Vietnam Hepatitis B Infection Market, By Treatment, 2022-2031 (Usd Million)
- Table 44 Vietnam Antiviral Drugs In Hepatitis B Infection Market, By Treatment, 2022-2031 (Usd Million)
- Table 45 Vietnam Immune Modulator Drugs In Hepatitis B Infection Market, By Treatment, 2022-2031 (Usd Million)
- Table 46 Vietnam Vaccine, Antiviral Drugs, Immune Modulator Drugs In Hepatitis B Infection Market, By Distribution Channel, 2022-2031 (Usd Million)
- Table 47 Philippines Hepatitis B Infection Market, By Type, 2022-2031 (Usd Million)
- Table 48 Philippines Hepatitis B Infection Market, By Treatment, 2022-2031 (Usd Million)
- Table 49 Philippines Antiviral Drugs In Hepatitis B Infection Market, By Treatment, 2022-2031 (Usd Million)
- Table 50 Philippines Immune Modulator Drugs In Hepatitis B Infection Market, By Treatment, 2022-2031 (Usd Million)
- Table 51 Philippines Vaccine, Antiviral Drugs, Immune Modulator Drugs In Hepatitis B Infection Market, By Distribution Channel, 2022-2031 (Usd Million)
- Table 52 Thailand Hepatitis B Infection Market, By Type, 2022-2031 (Usd Million)
- Table 53 Thailand Hepatitis B Infection Market, By Treatment, 2022-2031 (Usd Million)
- Table 54 Thailand Antiviral Drugs In Hepatitis B Infection Market, By Treatment, 2022-2031 (Usd Million)
- Table 55 Thailand Immune Modulator Drugs In Hepatitis B Infection Market, By Treatment, 2022-2031 (Usd Million)
- Table 56 Thailand Vaccine, Antiviral Drugs, Immune Modulator Drugs In Hepatitis B Infection Market, By Distribution Channel, 2022-2031 (Usd Million)
- Table 57 South Korea Hepatitis B Infection Market, By Type, 2022-2031 (Usd Million)
- Table 58 South Korea Hepatitis B Infection Market, By Treatment, 2022-2031 (Usd Million)
- Table 59 South Korea Antiviral Drugs In Hepatitis B Infection Market, By Treatment, 2022-2031 (Usd Million)
- Table 60 South Korea Immune Modulator Drugs In Hepatitis B Infection Market, By Treatment, 2022-2031 (Usd Million)
- Table 61 South Korea Vaccine, Antiviral Drugs, Immune Modulator Drugs In Hepatitis B Infection Market, By Distribution Channel, 2022-2031 (Usd Million)
- Table 62 Australia Hepatitis B Infection Market, By Type, 2022-2031 (Usd Million)
- Table 63 Australia Hepatitis B Infection Market, By Treatment, 2022-2031 (Usd Million)
- Table 64 Australia Antiviral Drugs In Hepatitis B Infection Market, By Treatment, 2022-2031 (Usd Million)
- Table 65 Australia Immune Modulator Drugs In Hepatitis B Infection Market, By Treatment, 2022-2031 (Usd Million)
- Table 66 Australia Vaccine, Antiviral Drugs, Immune Modulator Drugs In Hepatitis B Infection Market, By Distribution Channel, 2022-2031 (Usd Million)
- Table 67 Singapore Hepatitis B Infection Market, By Type, 2022-2031 (Usd Million)
- Table 68 Singapore Hepatitis B Infection Market, By Treatment, 2022-2031 (Usd Million)
- Table 69 Singapore Antiviral Drugs In Hepatitis B Infection Market, By Treatment, 2022-2031 (Usd Million)
- Table 70 Singapore Immune Modulator Drugs In Hepatitis B Infection Market, By Treatment, 2022-2031 (Usd Million)
- Table 71 Singapore Vaccine, Antiviral Drugs, Immune Modulator Drugs In Hepatitis B Infection Market, By Distribution Channel, 2022-2031 (Usd Million)
- Table 72 Malaysia Hepatitis B Infection Market, By Type, 2022-2031 (Usd Million)
- Table 73 Malaysia Hepatitis B Infection Market, By Treatment, 2022-2031 (Usd Million)
- Table 74 Malaysia Antiviral Drugs In Hepatitis B Infection Market, By Treatment, 2022-2031 (Usd Million)
- Table 75 Malaysia Immune Modulator Drugs In Hepatitis B Infection Market, By Treatment, 2022-2031 (Usd Million)
- Table 76 Malaysia Vaccine, Antiviral Drugs, Immune Modulator Drugs In Hepatitis B Infection Market, By Distribution Channel, 2022-2031 (Usd Million)
- Table 77 New Zealand Hepatitis B Infection Market, By Type, 2022-2031 (Usd Million)
- Table 78 New Zealand Hepatitis B Infection Market, By Treatment, 2022-2031 (Usd Million)
- Table 79 New Zealand Antiviral Drugs In Hepatitis B Infection Market, By Treatment, 2022-2031 (Usd Million)
- Table 80 New Zealand Immune Modulator Drugs In Hepatitis B Infection Market, By Treatment, 2022-2031 (Usd Million)
- Table 81 New Zealand Vaccine, Antiviral Drugs, Immune Modulator Drugs In Hepatitis B Infection Market, By Distribution Channel, 2022-2031 (Usd Million)
- Table 82 Taiwan Hepatitis B Infection Market, By Type, 2022-2031 (Usd Million)
- Table 83 Taiwan Hepatitis B Infection Market, By Treatment, 2022-2031 (Usd Million)
- Table 84 Taiwan Antiviral Drugs In Hepatitis B Infection Market, By Treatment, 2022-2031 (Usd Million)
- Table 85 Taiwan Immune Modulator Drugs In Hepatitis B Infection Market, By Treatment, 2022-2031 (Usd Million)
- Table 86 Taiwan Vaccine, Antiviral Drugs, Immune Modulator Drugs In Hepatitis B Infection Market, By Distribution Channel, 2022-2031 (Usd Million)
- Table 87 Rest Of Asia-pacific Hepatitis B Infection Market, By Type, 2022-2031 (Usd Million)
- Figure 1 Asia-pacific Hepatitis B Infection Market: Segmentation
- Figure 2 Asia-pacific Hepatitis B Infection Market: Data Triangulation
- Figure 3 Asia-pacific Hepatitis B Infection Market: Droc Analysis
- Figure 4 Asia-pacific Hepatitis B Infection Market: Asia-pacific Vs Regional Market Analysis
- Figure 5 Asia-pacific Hepatitis B Infection Market: Company Research Analysis
- Figure 6 Asia-pacific Hepatitis B Infection Market: Multivariate Modelling
- Figure 7 Asia-pacific Hepatitis B Infection Market: Interview Demographics
- Figure 8 Asia-pacific Hepatitis B Infection Market: Dbmr Market Position Grid
- Figure 9 Asia-pacific Hepatitis B Infection Market: Vendor Share Analysis
- Figure 10 Asia-pacific Hepatitis B Infection Market: Segmentation
- Figure 11 Two Segments Comprise The Asia-pacific Hepatitis B Infection Market, By Type
- Figure 12 Executive Summary
- Figure 13 Strategic Decisions
- Figure 14 Asia-pacific Hepatitis B Infection Market
- Figure 15 Chronic Segment Is Expected To Account For The Largest Share Of The Asia-pacific Hepatitis B Infection Market In 2024 & 2031
- Figure 16 Droc Analysis
- Figure 17 Burden Of Hbv Infection In The General Population By Who Region, 2019
- Figure 18 Asia-pacific Hepatitis B Infection Market: By Type, 2023
- Figure 19 Asia-pacific Hepatitis B Infection Market: By Type, 2024-2031 (Usd Million)
- Figure 20 Asia-pacific Hepatitis B Infection Market: By Type, Cagr (2024-2031)
- Figure 21 Asia-pacific Hepatitis B Infection Market: By Type, Lifeline Curve
- Figure 22 Asia-pacific Hepatitis B Infection Market: By Treatment, 2023
- Figure 23 Asia-pacific Hepatitis B Infection Market: By Treatment, 2024-2031 (Usd Million)
- Figure 24 Asia-pacific Hepatitis B Infection Market: By Treatment, Cagr (2024-2031)
- Figure 25 Asia-pacific Hepatitis B Infection Market By Treatment, Lifeline Curve
- Figure 26 Asia-pacific Hepatitis B Infection Market, Snapshot
- Figure 27 Asia-pacific Hepatitis B Treatment Market: Company Share 2023 (%)
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.